Hunan Er-Kang Pharmaceutical Co., Ltd (300267.SZ)
CNY 2.31
(2.67%)
CNY 2.31
(2.67%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 12.02 Million CNY | -105.42% |
| 2022 | 213.54 Million CNY | -21.46% |
| 2021 | -625.78 Million CNY | -43.9% |
| 2020 | 410.96 Million CNY | 20.83% |
| 2019 | 336.83 Million CNY | -16.38% |
| 2018 | 421.7 Million CNY | -41.52% |
| 2017 | 723.89 Million CNY | -26.89% |
| 2016 | 981.09 Million CNY | 37.19% |
| 2015 | 770.02 Million CNY | 80.71% |
| 2014 | 410.79 Million CNY | 56.11% |
| 2013 | 265.34 Million CNY | 29.26% |
| 2012 | 200.68 Million CNY | 32.12% |
| 2011 | 156.85 Million CNY | 66.09% |
| 2010 | 91.19 Million CNY | 178.43% |
| 2009 | 33.68 Million CNY | 63.78% |
| 2008 | 20.28 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | -30.33 Million CNY | -392.02% |
| 2024 Q1 | 2.05 Million CNY | 128.49% |
| 2024 Q2 | 9.89 Million CNY | -80.1% |
| 2023 Q2 | 8.76 Million CNY | -72.11% |
| 2023 Q1 | 31.41 Million CNY | 318.03% |
| 2023 Q3 | -1.71 Million CNY | -119.55% |
| 2023 Q4 | -183.2 Million CNY | -10596.35% |
| 2023 FY | - CNY | -105.42% |
| 2022 Q3 | -2.45 Million CNY | -119.27% |
| 2022 Q1 | 24.39 Million CNY | 119.22% |
| 2022 FY | - CNY | -21.46% |
| 2022 Q4 | -14.4 Million CNY | -487.74% |
| 2022 Q2 | 12.72 Million CNY | -47.85% |
| 2021 FY | - CNY | -43.9% |
| 2021 Q4 | -126.92 Million CNY | -292.74% |
| 2021 Q2 | 54.04 Million CNY | -10.54% |
| 2021 Q3 | 65.85 Million CNY | 21.84% |
| 2021 Q1 | 60.41 Million CNY | 15.81% |
| 2020 FY | - CNY | 20.83% |
| 2020 Q1 | 34.77 Million CNY | 105.21% |
| 2020 Q2 | 49.93 Million CNY | 43.59% |
| 2020 Q3 | 125.49 Million CNY | 151.3% |
| 2020 Q4 | 52.16 Million CNY | -58.43% |
| 2019 Q3 | 42.59 Million CNY | 14.47% |
| 2019 Q4 | 16.94 Million CNY | -60.22% |
| 2019 Q2 | 37.21 Million CNY | -68.69% |
| 2019 Q1 | 118.86 Million CNY | 322.83% |
| 2019 FY | - CNY | -16.38% |
| 2018 Q2 | 103.11 Million CNY | -32.12% |
| 2018 Q4 | -53.34 Million CNY | -157.4% |
| 2018 FY | - CNY | -41.52% |
| 2018 Q1 | 151.89 Million CNY | 1027.35% |
| 2018 Q3 | 92.93 Million CNY | -9.88% |
| 2017 Q2 | 253.97 Million CNY | 11.35% |
| 2017 FY | - CNY | -26.89% |
| 2017 Q3 | 156.4 Million CNY | -38.42% |
| 2017 Q4 | 13.47 Million CNY | -91.39% |
| 2017 Q1 | 228.08 Million CNY | 25.42% |
| 2016 FY | - CNY | 37.19% |
| 2016 Q3 | 192.4 Million CNY | -53.87% |
| 2016 Q2 | 417.09 Million CNY | 143.91% |
| 2016 Q4 | 181.85 Million CNY | -5.49% |
| 2016 Q1 | 171 Million CNY | 2.46% |
| 2015 Q1 | 99.82 Million CNY | -11.36% |
| 2015 Q4 | 166.89 Million CNY | 9.25% |
| 2015 Q3 | 152.75 Million CNY | -34.53% |
| 2015 Q2 | 233.32 Million CNY | 133.73% |
| 2015 FY | - CNY | 80.71% |
| 2014 Q2 | 92.49 Million CNY | 22.05% |
| 2014 Q3 | 62.45 Million CNY | -32.48% |
| 2014 Q4 | 112.62 Million CNY | 80.33% |
| 2014 FY | - CNY | 56.11% |
| 2014 Q1 | 75.77 Million CNY | -3.35% |
| 2013 Q2 | 56.31 Million CNY | 34.25% |
| 2013 Q3 | 54.01 Million CNY | -4.08% |
| 2013 Q4 | 78.4 Million CNY | 45.16% |
| 2013 FY | - CNY | 29.26% |
| 2013 Q1 | 41.94 Million CNY | -21.02% |
| 2012 Q3 | 37.57 Million CNY | -35.65% |
| 2012 Q2 | 58.39 Million CNY | 49.48% |
| 2012 FY | - CNY | 32.12% |
| 2012 Q1 | 39.06 Million CNY | 3.53% |
| 2012 Q4 | 53.11 Million CNY | 41.35% |
| 2011 Q1 | 19.83 Million CNY | -50.5% |
| 2011 Q2 | 53.38 Million CNY | 169.11% |
| 2011 Q4 | 37.73 Million CNY | 4.19% |
| 2011 Q3 | 36.21 Million CNY | -32.16% |
| 2011 FY | - CNY | 66.09% |
| 2010 FY | - CNY | 178.43% |
| 2010 Q4 | 40.07 Million CNY | 69.57% |
| 2010 Q3 | 23.63 Million CNY | 0.0% |
| 2009 FY | - CNY | 63.78% |
| 2008 FY | - CNY | 0.0% |